Cutaneous reactions to imatinib mesylate treated by topical steroid.
Ujiie
Hideyuki
H
Shimizu
Tadamichi
T
Shimizu
Hiroshi
H
D000279:Administration, Cutaneous; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D001623:Betamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003875:Drug Eruptions / Q000188:drug therapy* / Q000209:etiology; D005477:Fluprednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D009824:Ointments; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D013256:Steroids / Q000008:administration & dosage / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D009824:Ointments; D010879:Piperazines; D011743:Pyrimidines; D013256:Steroids; D000068877:Imatinib Mesylate; D001623:Betamethasone; D005477:Fluprednisolone; C021137:alclometasone dipropionate; C015808:difluprednate; C014477:diflorasone; D008775:Methylprednisolone